Geneva, Dec. 23 -- International Clinical Trials Registry received information related to the study (ISRCTN17069976) titled 'Investigation of whether a drug called azacitidine can be safely used to make patients with hypertrophic cardiomyopathy feel better' on Dec. 15.
Study Type: Interventional
Study Design:
Open randomized controlled trial (Efficacy, Safety)
Primary Sponsor: Belfast Health and Social Care Trust
Condition:
Hypertrophic cardiomyopathy (HCM)
Circulatory System
Intervention:
Phase 2a participants will all receive azacitidine treatment, with the dose being escalated/deescalated based on the TITE-CRM DLT model. During Phase 2b participants will be randomly assigned by 1:1 allocation to either azacitidine treatment ar...